Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Albumins
  • Antineoplastic Combined Chemotherapy Protocols
  • Deoxycytidine
  • Paclitaxel
  • Pancreatic Neoplasms

abstract

  • The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3565012

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.36.5742

PubMed ID

  • 21969517

Additional Document Info

start page

  • 4548

end page

  • 54

volume

  • 29

number

  • 34